Pre-made Tavolimab benchmark antibody ( Whole mAb, anti-TNFSF4/OX40 therapeutic antibody, Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-553

Pre-Made Tavolimab biosimilar, Whole mAb, Anti-TNFSF4/OX40 Antibody: Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tavolimab (MEDI 0562), a humanised IgG1κ monoclonal antibody agonist of OX40, was being developed by MedImmune for the treatment of solid tumours, including ovarian cancer.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-553-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Tavolimab biosimilar, Whole mAb, Anti-TNFSF4/OX40 Antibody: Anti-CD134L/CD252/GP34/OX-40L/OX4OL/TNLG2B/TXGP1 therapeutic antibody
INN Name Tavolimab
TargetOX40
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2018
CompaniesEuropean Network of Gynaecological Oncological Trial Groups;MedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedOvarian cancer;Solid tumours
Development Techna